Measles virus infection and vaccination: Potential role in chronic illness and associated adverse events

Critical Reviews in Immunology

Volumn 24, Issue 2, 2004, Pages 129-156

  Kennedy, Ronald C ^a   Byers, Vera S ^b   Marchalonis, John J ^c  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Antibodies; Autism; Cytokines; T cells

Indexed keywords

ANTIBIOTIC AGENT; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; INACTIVATED VACCINE; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; POLIOMYELITIS VACCINE; SIGNALING LYMPHOCYTE ACTIVATION MOLECULE ASSOCIATED PROTEIN;

ANAPHYLAXIS; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ARTHROPATHY; ASEPTIC MENINGITIS; AUTISM; CELL POLARITY; CELLULAR IMMUNITY; CHILD HEALTH CARE; COLITIS; CYTOKINE PRODUCTION; CYTOPENIA; DELAYED HYPERSENSITIVITY; DRUG CONTRAINDICATION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MANUFACTURE; ENCEPHALITIS; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GUILLAIN BARRE SYNDROME; HISTORY OF MEDICINE; HUMAN; ILEITIS; IMMUNE RESPONSE; IMMUNIZATION; LYMPHOCYTOPENIA; MEASLES; MEASLES VACCINATION; MEASLES VIRUS; MENINGOENCEPHALITIS; MENTAL DEFICIENCY; MUMPS; NEUROLOGIC DISEASE; NONHUMAN; OTITIS MEDIA; OTOSCLEROSIS; PATHOGENESIS; PERSISTENT VIRUS INFECTION; PNEUMONIA; PRIORITY JOURNAL; REVIEW; RUBELLA; SIDE EFFECT; SPEECH DISORDER; SUBACUTE SCLEROSING PANENCEPHALITIS; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; VIRUS GENOME; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION; VIRUS VIRULENCE;

AUTISTIC DISORDER; HUMANS; IMMUNITY, ACTIVE; MEASLES; MEASLES VIRUS; MEASLES-MUMPS-RUBELLA VACCINE; MODELS, BIOLOGICAL; T-LYMPHOCYTES; VIRUS REPLICATION;

EID: 10644220988     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevImmunol.v24.i2.30     Document Type: Review

References (234)

1. Smith T. Measles and the government. Br Med J 1987;294:989-990.
2. Institute of Medicine. Measles and mumps vaccines. Washington, DC: National Academy Press; 1991. p. 120-185.
3. MMWR. Update: vaccine side effects, adverse reactions, contraindication and precautions. Recommendations of the Advisory Committee on Immunization Practices. Morb Mortal Wkly Rep 1996;45:1-35 (RR-12).
4. Afzal MA, Minor PD, Schild GC. Clinical safety issues of measles, mumps and rubella vaccines. Bull World Health Organ 2000;78:199-204.
5. Wilson CA, Marcuse EK. Vaccine safety-vaccine benefits: science and the public's perception. Nat Rev Immunol 2001;1:69-75.
6. Institute of Medicine. Measles-Mumps-Rubella Vaccine and Autism. Immunization Safety Review; 2001.
7. Stephenson J. Will the current measles vaccines ever eradicate measles? Expert Rev Vaccines 2002;1:355-362.
8. Peltola H, Patja A, Leinikki P, Valle M, Davidkin I, Paunio M. No evidence for measles, mumps, and rubella vaccine associated inflammatory bowel disease or autism in a 14-year prospective study. Lancet 1998;351:1327-1328.
9. Clements CJ, Cutts FT. The epidemiology of measles: thirty years of vaccination. Curr Topics Microbiol Immunol 1995;191:13-33.
10. Enders JF, Katz SL, Holloway A. Development of attenuated measles virus vaccines. Am J Dis Child 1962;103:165-170.
11. Hillman M, Buynak E, Weibel R, Stokes J, Whitman J, Leagus B. Development and evaluation of the Moraten measles virus vaccine. J Am Med Assoc 1968;206:587-590.
12. Markowitz LE, Katz SL. Measles vaccine. In: Plotkin SA, Mortimer EA Jr, editors. Vaccines. WB Sanders; 1994: p. 229-276.
13. Valsamakis A, Kaneshima H, Griffin DE. Strains of measles vaccine differ in their ability to replicate in and damage human thymus. J Infect Dis 2001;183:498-502.
14. Physicians' Desk Reference. 2000;54:1819-1822.
15. MMWR. Measles prevention. Morb Mortal Wkly Rep 1989;38(Suppl 9):1-18.
16. MMWR. Recommended childhood immunization schedule - United States July-December. Advisory Committee on Immunization Practices, the American Academy of Pediatrics, the American Academy of Family Physicians, and the Food and Drug Administration. Morb Mortal Wkly Rep 1996;45:635-638.
17. Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L. Measles, mumps, and rubella - vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendation of the Advisory Committee on Immunization Practices. Morb Mortal Wkly Rep 1998;47:1-57.
18. Davis RL, Marcuse E, Black S, Shinefield HY, Givens B, Schwalbe J, Ray P, Thompson RS, Chen R. MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the vaccine safety datalink project. The vaccine safety datalink team. Pediatrics 1997;100:767-771.
19. Sonnen G, Henry N. Measles. In: Wilson WR, Sande MA, editors. Current diagnosis and treatment in infectious diseases. New York McGraw-Hill; 2001. p. 413-420.
20. Physicians' Desk Reference. 1997;51:1731-1732.
21. MMWR. Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection, 1993. Morb Mortal Wkly Rep 1996;45:603-606.
22. American Academy of Pediatrics. Committee on Infectious Diseases: Haemphilus influenzae type b conjugate vaccines: update. Pediatrics 1989;84:386-387.
23. Mustafa MM, Weitman SD, Winick NJ, Bulini WJ, Timmons CF, Siegel JD. Subacute measles encephalitis in the young immunocompromised host: report of two cases diagnosed by polymerase chain reaction and treated with ribavirin and review of the literature. Clin Infect Dis 1993;16:654-660.
24. Drysdale HC, Jones LF, Openheimer DR, Tomilinson AH. Measles inclusion body encephalitis in a child with treated acute lymphoblastic leukemia. J Clin Pathol 1976;29:865-872.
25. Murphy JV, Yunis EJ. Encephalopathy following measles infection in children with chronic illness. J Pediatr 1976;88:937-942.
26. Aicardi J, Goutieres F, Arsenio-Nunes M-L, Lebon P. Acute measles encephalitis in children with immunosuppression. Pediatrics 1977;59:232-239.
27. Hughes I, Jenney M, Newton R, Morris D, Klapper P. Measles encephalitis during immunosuppressive treatment for acute lymphoblastic leukemia. Arch Dis Child 1993;68:775-778.
28. Monafo W, Haslam D, Roberts RL, Zaik S, Bellini W, Coffin C. Disseminated measles infection after vaccination in a child with a congenital immunodeficiency. J Pediatr 1994;124:273-276.
29. Sonoda S, Kitahara M, Nakayama T. Detection of measles virus genome in bone marrow aspirates from adults. J Gen Virol 2002;83:2485-2488.
30. Duchini A, Goss JA, Karpen S, Pockros PJ. Vaccinations for adult solid-organ transplant recipients: current recommendations and protocol. Clin Microbiol Rev 2003;16:357-364.
31. Nader PR, Warren RJ. Reported neurologic disorders following live measles vaccine. Pediatrics 1968;41:997-1001.
32. Schneck SA. Vaccination with measles and central nervous system disease. Neurology 1968;18:79-82.
33. Landrigan P, Witte J. Neurologic disorders following live measles virus vaccination. J Am Med Assoc 1973;223:1459-1462.
34. Seager C, Moriarity J, Ngai A, Staehle BO, Nalin DR. Low incidence of adverse experiences after measles or measles-rubella mass revaccination at a college campus. Vaccine 1994;12:1018-1020.
35. Warren RP, Margaretten NC, Pace NC, Foster A. Immune abnormalities in patients with autism. J Autism Dev Disord 1986;16:189-197.
36. Dales L, Hammer SJ, Smith N. Time trends in autism and in MMR immunization coverage in California. J Am Med Assoc 2001;285:1183-1185.
37. Gillberg C, Heijbel H. MMR and autism. Autism 1998;2:423-424.
38. Kaye JA, del Mar Melero-Montes M, Jick H. Mumps, measles, and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis. Br Med J 2001;322:460-463.
39. Patja A, Davidkin I, Kurki T, Kallio MJ, Valle M, Peltola H. Serious adverse events after measles-mumps-rubella vaccination during a fourteen year prospective follow-up. Pediatr Infect Dis J 2000;19:1127-1134.
40. Taylor B, Miller E, Farrington CP, Petropoulos MC, Favot-Mayaud I, Li J, Waight PA. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence of a causal association. Lancet 1999;351:1927.
41. Farrington P, Miller E, Taylor B. MMR and autism: further evidence against a causal association. Vaccine 2001;19:3632-3635.
42. Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M, Berelowitz M, Dhillon A, Thomson M, Harvey P, Valentine A, Davies S, Walker-Smith J. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998;351:637-641.
43. Black SB, and the Centers for Disease Control and Prevention Vaccine Safety Datalink Working Group. The risk of seizures after receipt of whole cell pertussis or measles, mumps, rubella vaccine. N Engl J Med 2001;345:656-661.
44. Madsen KM, Hviid A, Vestegaard M, Schendel D, Wohlfahrt J, Thorse P, Olsen J, Melbye M. A population based study of measles, mumps, and rubella vaccination and autism. N Engl J Med 2002;347:1477-1482.
45. Taylor B, Miller E, Lingam R, Andrews N, Simmons A, Stowe J. Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. Br Med J 2002;324:393-396.
46. Fournier J-G, Lebon P, Bouteille M, Goutieres F, Rozenblatt S. Subacute sclerosing panencephalitis: detection of measles virus RNA in appendix lymphoid tissue before clinical signs. Br Med J 1986;293:523-524.
47. Morris DL, Montgomery SM, Thompson NP, Ebrahim S, Punder RE, Wakefield AJ. Measles vaccination and inflammatory bowel disease: a national British Cohort Study. Am J Gastroenterol 2000;95:3507-3512.
48. Afzal MA, Armitage E, Begley J, Bentley ML, Minor PD, Ghosh S, Ferguson A. Absence of detectable meales virus genome sequence in inflammatory bowel disease tissues and peripheral blood lymphocytes. J Med Virol 1998;55:243-249.
49. Chadwick N, Bruce I, Schepelmann S, Pounder R, Wakefield A. Measles virus RNA is not detected in inflammatory bowel disease using hybrid capture and reverse transcriptions followed by the polymerase chain reaction. J Med Virol 1998;55:305-311.
50. Afzal MA, Armitage E, Ghosh S, Williams LC, Minor PD. Further evidence of the absence of measles virus genome sequence in full thickness intestinal specimens from patients with Crohn's disease. J Med Virol 2000;62:377-382.
51. Wakefield A, Pittilo R, Sim R, Cosby S, Stephenson J, Dhillon A, Pounder R. Evidence of persistent measles virus infection in Crohn's disease. J Med Virol 1993;39:345-353.
52. Daszak P, Purcell M, Lewin J, Dhillon A, Pounder R, Wakefield A. Detection and comparative analysis of persistent measles virus infection in Crohn's disease by immunogold electron microscopy. J Clin Pathol 1997;50:299-304.
53. Kawashima H, Mori T, Kashiwagi Y, Takekuma K, Hoshika A, Wakefield A. Detection and sequencing of measles virus from peripheral mononuclear cells from patients with inflammatory bowel disease and autism. Dig Dis Sci 2000;45:723-729.
54. Martin CM, Uhlmann V, Killalea A, Sheils O, O'Leary JJ. Detection of measles virus in children with ileocolonic lymphoid nodular hyperplasia, enterocolitis and developmental disorder. Mol Psychiat 2002;7:S47-S48.
55. Uhlmann V, Martin CM, Sheils O, Pilkington L, Silva I, Killalea A, Murch SB, Walker-Smith J, Thomson M, Wakefield AJ, O'Leary JJ. Potential viral pathogenic mechanism for new variant inflammatory bowel disease. Mol Pathol 2002;55:84-90.
56. Vieth M, Dirshmid K, Oehler U, Helpap B, von Luckner AG, Stolte M. Acute measles gastric infection. Am J Surg Pathol 2001;25:259-262.
57. Reyes MA, de Borrero MF, Roa J, Bergonzoli G, Saravia NG. Measles vaccine failure after documented seroconversion. Pediatr Infect Dis J 1987;6:848-851.
58. Poland G, Jacobson R. Failure to reach the goal of measles elimination: apparent paradox of measles infections in immunized persons. Arch Intern Med 1994;154:1815-1820.
59. Schneider-Schaulies J, Niewiesk S, Scheider-Schaulies S, ter Meulen V. Measles virus in the CNS: the role of viral and host factors for the establishment and maintenance of a persistent infection. J Neurovirol 1999;5:613-622.
60. McGee ZA. Infections of the Central Nervous System. In: Wilson WR, Sande MA, editors. Current diagnosis and treatment in infectious diseases. New York: McGraw-Hill; 2001: p. 65-84.
61. Wild TF, Bernard A, Greenland T. Measles virus: evolution of a persistent infection in BGM cells. Arch Virol 1981;67:297-308.
62. Anderton P, Wild TF, Zwingelstein G. Measles virus persistent infection in BGM cells. Biochem J 1983;214:665-670.
63. Gopas J, Itzhaky D, Segev Y, Salzberg S, Trink B, Isakov N, Rager-Zisman B. Persistent measles virus infection enhances major histocompatibility complex class I expression and immunogenicity of murine neuroblastoma cells. Cancer Immunol Immunother 1992;34:313-320.
64. Schneider-Schaulies J, Schneider-Schaulies S, ter Meulen V. Differential induction of cytokines by primary and persistent measles virus infections in human glial cells. Virology 1993;195:219-228.
65. Goldman MB, Buckthal DJ, Picciotto S, O'Bryan T, Goldman JN. Measles virus persistence in an immortalized murine macrophage cell line. Virology 1995;207:12-22.
66. Cattaneo R, Rebmann G, Baczko K, ter Meulen V, Billeter MA. Altered ratios of measles virus transcripts in diseased human brains. Virology 1987;160:523-526.
67. Cattaneo R, Schmid A, Spielhofer P, Kaelin K, Baczko K, ter Meulen V, Pardowitz J, Flanagan S, Rima B, Udem S, Billeter M. Mutated and hypermutated genes of persistent measles viruses which caused lethal human brain diseases. Virology 1989;173:415-425.
68. Hirano A. Subacute sclerosing panencephalitis virus dominantly interferes with replication of wild type measles virus in a mixed infection: implication for viral persistence. J Virol 1992;66:1891-1898.
69. Lewin J, Dhillon A, Sim R, Mazure G, Pounder R, Wakefield A. Persistent measles virus infection of the intestine: confirmation by immunogold electron microscopy. Gut 1995;36:564-569.
70. Rima BK, Davidson WB, Martin SJ. The role of defective interfering particles in persistent infection of vero cells by measles virus. J Gen Virol 1977;35:89-97.
71. Calain P, Roux L. Generation of measles virus defective interfering particles and their presence in a preparation of attenuated live virus vaccine. J Virol 1988;62:2859-2866.
72. Sidhu MS, Crowley J, Lowenthal A, Darcher D, Menoona J, Cook S, Udem S, Dowling P. Defective measles virus in human subacute sclerosing panencephalitis brain. Virology 1994;202:631-641.
73. Yant S, Hirano A, Wong TC. Identification of a cytoplasmic Tyr-X-X-Leu motif essential for down regulation of the human cell receptor for CD46 in persistent measles virus infection. J Virol 1997;71:766-770.
74. Oldstone MBA. Viruses can cause disease in the absence of morphological evidence of cell injury: implication for uncovering new diseases in the future. J Infect Dis 1989;159:384-389.
75. Gaston J, Yon E, Godfrey H, Helhaye-Bouchaud N, Mariani J. An animal mode of autism: behavioral studies in the GS guinea pig. Eur J Neurosci 1998;10:2677-2684.
76. Pletnikov MV, Moran TH, Carbone KM. Developmental brain injury associated with abnormal play behavior in neonatally Borna disease virus infected Lewis rats: a model of autism. Behavioral Brain Res 1999;100:43-50.
77. Carbone KM, Rubin SA, Pletnikov M. Borna disease virus induced model of autism: application to vaccine safety test design. Mol Psychiatry 2002;7:S36-S37.
78. Chen RT, Rastogi SC, Mullen JR, Hayes SW, Cochi SL, Donlon JA, Wassilak SG. The vaccine adverse event reporting system (VAERS). Vaccine 1994;12:542-550.
79. Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, Haber P, Pless RP, Mootrey G, Ellenberg SS, Braun MM, Chen RT. Surveillance for safety after immunization: vaccine adverse event reporting systems (VAERS) - United States, 1991-2001. MMWR Surveill Summ 2003;52:1-24.
80. Anlar B, Lktem F, Torok T. Human parvovirus B19 antibodies in infantile autism. J Child Neurol 1994;9:104-105.
81. Singh VK, Lin SX, Yang VC. Serological association of measles virus and human herpesvirus with brain autoantibodies in autism. Clin Immunol Immunopathol 1998;89:105-108.
82. Barak Y, Kimhi R, Stein D, Gutman J, Weizman A. Autistic subjects with comorbid epilepsy: a possible association with viral infections. Child Psychiatry Hum Dev 1999;29:245-251.
83. Barlow WE, Davis RL, Classer JW, Rhodes PH, Thompson RS, Mullool JP, et al. The risk of seizures after receipt of whole cell pertussis or measles, mumps, rubella vaccine. N Engl J Med 2001;345:656-661.
84. Kobune F, Takahashi H, Terao K, Ohkawa T, Ami Y, Suzaki Y, Nagata N, Sakata H, Yamanouchi K, Kai C. Nonhuman primate models of measles. Lab Anim Sci 1996;46:315-320.
85. Benjamin C, Silman A. Adverse reactions and measles mumps rubella vaccine. J Pub Health Med 1991;13:32-34.
86. Chen R, Moses J, Markowitz L, Orenstein W. Adverse events following measles-mumps-rubella and measles vaccination in college students. Vaccine 1991;9:297-299.
87. Duclos P, Ward BJ. Measles vaccines: a review of adverse events. Drug Saftey 1998;19:435-454.
88. Abe T, Nonaka C, Hiraiwa M, Ushijima H, Fugii R. Acute and delayed neurologic reaction to inoculation with attenuated live measles virus. Brain Dev 1985;7:421-423.
89. Grose C, Spigland I. Guillain-Barre Syndrome following administration of live measles vaccine. Am J Med 1976;60:441-443.
90. Da Silveira C, Salisbury D, De Quadros C. Measles vaccination and Guillian-Barre syndrome. Lancet 1997;349:14-16.
91. Benjamin C, Chew G, Silman A. Joint and limb symptoms in children after immunization with measles mumps and rubella vaccine. Br Med J 1992;304:1075-1078.
92. Jagdis F, Langston C, Gurwith M. Encephalitis after administration of live measles vaccine. Can Med Assoc J 1975;112:972-975.
93. Valmari P, Lanning M, Tuokko H, Kouvalainene K. Measles virus in the cerebrospinal fluid in postvaccination immunosuppressive measles encephalopathy. Pediatr Infect Dis J 1987;6:59-63.
94. Bitnun A, Shannon P, Durward A, Rota P, Bellini W, Graham C, Wang E, Ford-Jones E, Cox P, Becker L, Fearon M, Petric M, Tellier R. Measles inclusion body encephalitis caused by the vaccine strain of measles virus. Clin Infect Dis 1999;29:855-861.
95. Cizman M, Mozetic M, Radescek-Rakar R, Pleterski-Rigler D, Susec-Michieli M. Aseptic meningitis after vaccination against measles and mumps. Pediatr Infect Dis J 1989;8:302-308.
96. Black S, Shinefield H, Ray P, Lewis E, Chen R, Classer J, Hadler S, Hardy J, Rhodes P, Swint E, Davis R, Thompson R, Mullooly J, Marcy M, Vadheim C, Ward J, Rastogi S, Wise R. Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one-to two-year old children: an anaylsis of the Vaccine Safety Datalink (VSD) project. Pediatr Infect Dis J 1997;16:500-503.
97. Da Cunha SS, Rodrigues LC, Barreto ML, Dourado I. Outbreak of aseptic meningitis and mumps after mass vaccination with MMR vaccine using the Leningrad-Zagreb mumps strain. Vaccine 2002;20:1106-1112.
98. Galbraith SE, McQuaid S, Hamill L, Pullen L, Barrett T, Cosby SL. Rinderpest and peste des petitis ruminants viruses exhibit neurovirulence in mice. J Neurovirol 2002;8:45-52.
99. Liebert UG. Measles virus infection of the central nervous system. Intervirology 1997;40:176-184.
100. Oldstone M, Lewicki H, Thomas D, Tishon A, Dales S, Patterson J, Manchester M, Homann D, Naniche D, Holz A. Measles virus infection in transgenic model: virus induced immunosuppression and central nervous system disease. Cell 1999;98:629-640.
101. Zhu Y, Heath J, Collins J, Greene T, Antipa L, Rota P, Bellini W, McChesney M. Experimental measles: II. Infection and immunity in the rhesus macaque. Virology 1997;233:85-92.
102. Van Binnendijk RS, van der Heijden RWJ, Osterhaus ADME. Monkeys in measles virus research. Curr Top Microbiol Immunol 1995;191:135-148.
103. Permar SR, Moss WJ, Ryon JJ, Douek DC, Monze M, Griffin DE. Increased thymic output during acute measles virus infection. J Virol 2003;77:7872-7879.
104. Albrecht P, Burnstein T, Klutch MJ, Hicks JT, Ennis FA. Subacute sclerosing panencephalitis: experimental infection in primates. Science 1977;195:64-66.
105. McChesney MB, Fujinami RS, Lerche NW, Marx PA, Oldstone MBA. Virus induced immunosuppression: infection of peripheral blood mononuclear cells and suppression of immunoglobulin synthesis during natural measles virus infection of rhesus monkeys. J Infect Dis 1989;159:757-760.
106. Auwaerter P, Rota P, Elkins R, Adams J, deLozier T, Shi Y, Bellini W, Murphy B, Griffin E. Measles virus infection in rhesus macaques: altered immune responses and comparison of the virulence of six different virus strains. J Infect Dis 1999;180:950-958.
107. Choi YK, Simon MA, Kim DY, Yoon BI, Kwon SW, Lee KW, Seo IB, Kim DY. Fatal measles virus infection in Japanese macaques. Vet Pathol 1999;36:594-600.
108. Albrecht P, Lorenz D, Klutch MJ, Vickers JH, Ennis FA. Fatal measles infection in marmosets pathogenesis and prophylaxis. Infect Immun 1980;27:969-978.
109. Esolen LM, Takahasi K, Johnson RT, Vaisberg A, Moench TR, Weselingh SL, Griffin DE. Brain endothelial cell infection in children with acute fatal measles. J Clin Invest 1995;96:2478-2481.
110. Ohuchi M, Ohuchi R, Mifune K, Ishihara T, Ogawa T. Characterization of the measles virus isolated from the brain of a patient with immunosuppressive measles encephalitis. J Infect Dis 1987;156:436-441.
111. Dorig RE, Marcil A, Chopra A, Richardson CD. The human CD46 molecule is a receptor of measles virus (Edmonston strain). Cell 1993;75:295-305.
112. Erlenhofer C, Duprex WP, Rima BK, ter Meulen V, Schneider-Schaulies J. Analysis of receptor (CD46, CD150) usage by measles virus. J Gen Virol 2002;83:1431-1436.
113. Cosby SL, Duprex WP, Hamill LA, Ludlow M, McQuaid S. Approaches in understanding morbillivirus neurovirulence. J Neurovirol 2002;2S:85-90.
114. Moore JP, Trkola A, Dragic T. Co-receptors for HIV-1 entry. Curr Opin Immunol 1997;9:549-550.
115. Katz SL, Gellin BG. Measles: state of the art and future directions. J Infect Dis 1994;170:S3-S14.
116. Permar SR, Moss WJ, Ryon JJ, Monze M, Cutts F, Quinn TC, Griffin DE. Prolonged measles virus shedding in human immunodeficiency virus infected children detected by reverse transcriptase-polymerase chain reaction. J Infect Dis 2001;183:532-538.
117. McKenna MJ, Mills BG. Imunohistochemical evidence of measles virus antigens in active otosclerosis. Otolaryngol Head Neck Surg 1989;101:415-421.
118. McKenna MJ, Kristiansen AG, Haines J. Polymerase chain reaction amplification of a measles virus sequence from human temporal bone sections with active otosclerosis. Am J Otology 1996;17:827-830.
119. Wairagkar N, Gandhi B, Katrak S, Shaikh N, Parikh P, Wadia N, Gadkari D. Acute renal failure with neurological involvement in adults associated with measles virus isolation. Lancet 1999;354:992-995.
120. Nagai K, Mori T. Acute disseminated encephalomyelitis with probable measles vaccine failure. Pediatr Neurol 1999;20:399-402.
121. Okuno Y, Nakao T, Isihida N, Konno T, Mizutani H, Fukuyama Y, Sato T, Isomura S, Ueda S, Kitamura I, Kaji M. Incidence of subacute sclerosing panencephalitis and measles vaccination in Japan. Int J Epidemiol 1989;18:684-689.
122. Beersman MFC, Galama JMD, Van Druten HAM, Renier WO, Lucas CJ, Kapsenberg JG. Subacute sclerosing panencephalitis in the Netherlands 1976-1990. Int J Epidemiol 1992;21:583-588.
123. Sharova O, Bogomolova N, Koptyaaeva I, Gordienko N, Rozino E. Pathomorphologic characterization of CNS damage in monkeys infected with persistent variant of measles virus vaccine strain L-16. Acta Virol 1987;31:346-351.
124. Cruzado D, Masserey-Spicher V, Roux L, Delavell J, Picard F, Haenggeli C-A. Early onset and rapidly progressive subacute sclerosing panencephalitis after congenital measles infection. J Pediatr 2002;161:438-441.
125. Schneider-Schaulies S, Kreth HW, Hofmann G, Billeter M, ter Meulen V. Expression of measles virus RNA in peripheral blood mononuclear cells of patients with measles, SSPE, and autoimmune diseases. Virology 1991;182:703-711.
126. Hall WW, Choppin PW. Measles virus proteins in the brain tissue of patients with subacute sclerosing panencephalitis. New Engl J Med 1981;304:1152-1155.
127. Liebert UG, Baczko K, Budka H, ter Meulen V. Restricted expression of measles virus proteins in brains from cases of subacute sclerosing panencephalitis. J Gen Virol 1986;67:2435-2444.
128. Kirk J, Zhou A-L, McQuaid S, Cosby SL, Allen IV. Cerebral endothelial cell infection by measles virus in sub acute sclerosing panencephalitis: ultra structural and in situ hybridization evidence. Neuropathol Appl Neurobiol 1991;17:289-297.
129. Brown HR, Goller NL, Ruddelli RD, Dymecki J, Wisniewski HM. Postmortem detection of measles virus in non-neural tissues in subacute sclerosing panencephalitis. Ann Neurol 1989;26:263-268.
130. Esolen LM, Ward BJ, Moench TR, Griffin DE. Infection of monocytes during measles. J Infect Dis 1993;168:47-52.
131. Baram T, Gonzalez-Gomez I, Xie Z, Yao D, Gilles F, Nelson M, Nguyen H, Peters J. Subacute panencephalitis in an infant: diagnostic role of viral genome analysis. Ann Neurol 1994;36:103-108.
132. Ehrengruber MU, Ehler E, Billeter MA, Naim HY. Measles virus spreads in rat hippocampal neurons by cell to cell contact and in a polarized fashion. J Virol 2002;76:5720-5728.
133. Plumb J, Dumprex WP, Cameron CHS, Richter-Landsberg C, Talbot P, McQuaid S. Infection of human oligodendroglioma cells by a recombinant measles virus expressing enhanced green fluorescent protein. J Neurovirol 2002;8:24-34.
134. Sever JL. Persistent measles virus infection of the central nervous system: subacute sclerosing panaencephalitis. Rev Infect Dis 1983;5:1753-1760.
135. Sonoda S, Kitahara M, Nakayama T. Detection of measles virus genome in bone-marrow aspirates from adults. J Gen Virol 2002;83:2485-2488.
136. Wilson WR, Sande MA, editors. Current diagnosis and treatment in infectious diseases. East Norwalk, CT: Lange Medical Books; 2001.
137. Fulginiti V, Eller J, Downie A, Kempe H. Altered reactivity to measles virus: atypical measles in children previously immunized with inactivated measles virus vaccines. J Am Med Assoc 1967;202:101-106.
138. Brodsky AL. Atypical measles:severe illness in recipients of killed measles virus vaccine upon exposure to natural infection. J Am Med Assoc 1972;222:1415-1416.
139. Cherry JD, Feigin RD, Lobes LA, Shackelford PG. Atypical measles in children previously immunized with attenuated measles virus vaccines. Pediatrics 1972;50:712-717.
140. Fulginiti VA, Heifer RE. Atypical measles in adolescent siblings 16 years after killed measles virus vaccine. J Am Med Assoc 1980;244:804-806.
141. Annunziato D, Kaplan MH, Wall WW, Ichinose H, Lin JH, Balsam D, Paladino VS. Atypical measles syndrome:pathologic and serologic findings. Pediatrics 1982;70:203-209.
142. Pullan CR, Noble TC, Scott DJ, Wisniewski K, Gardner PS. Atypical measles infections in leukaemic children on immunosuppressive treatment. Br Med J 1976;1:1562-1565.
143. Polack FP, Auwaerter PG, Lee S-H, Nousari HC, Valsamakis A, Leiferman KM, Diwan A, Adams RJ, Griffin DE. Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion inhibiting antibody. Nat Med 1999;5:629-634.
144. Polack FP, Hoffman SJ, Moss WJ, Griffin DE. Altered synthesis of interleukin-12 and type 1 and type 2 cytokines in rhesus monkeys during measles and atypical measles. J Infect Dis 2002;185:13-19.
145. Morfin F, Beguin A, Lina B, Thouvenot D. Detection of measles vaccine in the throat of a vaccinated child. Vaccine 2002;20:1541-1543.
146. Rotal P, Khan A, Durigon E, Yuran T, Villamarzo Y, Bellini W. Detection of measles virus RNA in urine specimens from vaccine recipients. J Clin Microbiol 1995;33:2485-2488.
147. Vardas E, Kreis S. Isolation of measles from a naturally immune, asymptomatically re-infected individual. J Clin Virol 1999;13:173-179.
148. Weibel R, Buynak E, McLean A, Hilleman M. Longterm follow-up for immunity after monovalent or combined live measles, mumps, and rubella vaccines. Pediatrics 1975;56:380-387.
149. Weibel RA, Buynak EB, McLean AA, Hilleman MR. Persistence of antibody after administration of monovalent and combined live attenuated measles, mumps, rubella virus vaccines. Pediatrics 1978;61:5-11.
150. Markowitz L, Preblud S, Fine P, Orenstein W. Duration of live measles vaccine induced immunity. Pediatr Infect Dis J 1990;9:101-110.
151. Weibel RE, Buynak EB, McLean AA, Roehm RR, Hilleman MR. Persistence of antibody in human subjects 7-10 years following administration of combined live attenuated measles, mumps, and rubella virus vaccine. Proc Soc Exp Bio Med 1980;165:260-263.
152. Miller E, Hill A, Morgan-Capner P, Forsey T, Rush M. Antibodies to measles, mumps and rubella in UK children years after vaccination with different MMR vaccines. Vaccine 1995;13:799-802.
153. Isa MB, Martinez L, Giordano M, Passeggi C, de Wolff MC, Nates S. Comparison of immunoglobulin G subclass profiles induced by measles virus in vaccinated and naturally infected individuals. Clin Diag Lab Immunol 2002;9:693-697.
154. Christenson B, Bottiger M. Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus. Vaccine 1994;12:129-133.
155. Muller CP, Huiss S, Schneider F. Secondary immune responses in parents of children with recent measles. Lancet 1996;348:1379-1380.
156. Huiss S, Damien B, Schneider F, Muller CP. Characteristics of asymptomatic secondary immune responses to measles virus in late convalescent donors. Clin Exp Immunol 1997;109:416-420.
157. Brody JA, Overfield T, Hammes L. Depression of the tuberculin reaction by viral vaccines. N Eng J Med 1964;271:1294-1296.
158. Fireman P, Friday G, Kumate J. Effect of measles vaccine on immunologic responsiveness. Pediatrics 1969;43:264-272.
159. Munyer TP, Mangi RJ, Dolan T, Kantor FS. Depressed lymphocyte function after measles-mumps-rubella vaccination. J Infect Dis 1975;132:75-78.
160. Arneborn P, Biberfeld G. T lymphocytes subpopulations in relation to immunosuppression in measles and varicella. Infect Immun 1983;39:29-37.
161. Okada H, Sato TA, Katayama A, Higuchi K, Shichijo K, Tsuchiya T, Takayama N, Takeuchim Y, Abe T, Okabe N, Tashiro M. Comparative analysis of host responses relate to immunosuppression between measles patients and vaccine recipients with live attenuated measles vaccines. Arch Virol 2001;146:859-874.
162. Fugier-Vivier I, Servet-Delprat C, Rivailler P, Rissoan MC, Liu YJ, Rabourdin-Combe C. Measles virus suppresses cell mediated immunity by interfering with the survival and functions of dendritic and T cells. J Exp Med 1997;186:813-823.
163. Grosjean I, Caux C, Bella C, Berger I, Wild F, Banchereau J, Kaiserlian D. Measles virus infects human dendritic cells and blocks their allostimulatory properties for CD4+ T cells. J Exp Med 1997;186:801-812.
164. Schnorr J-J, Xanthakos S, Keikavoussi P, Kampgen E, ter Meulen V, Schneider-Schaulies S. Induction of maturation of human blood dendritic cell precursors by measles virus is associated with immunosuppression. Proc Natl Acad Sci U S A 1997;94:5326-5331.
165. Niewiesk S, Gotzelmann M, ter Meulen V. Selective in vivo suppression of T lymphocyte responses in experimental measles virus infection. Proc Natl Acad Sci U S A 2000;97:4251-4255.
166. McChesney MB, Altman A, Oldstone MBA. Suppression of T lymphocyte function by measles virus is due to cell cycle arrest in G1. J Immunol 1988;140:1269-1273.
167. Niewiesk S, Ohnimus H, Schnorr JJ, Gotzelmann M, Schneider-Schaulier S, Jassoy C, ter Meulen V. Measles virus induced immunosuppression in cotton rats is associated with cell cycle retarding in uninfected lymphocytes. J Gen Virol 1999;80:2023-2029.
168. Karp C, Wysocka M, Wahl L, Ahearn J, Cuomo P, Sherry B, Trinchieri G, Griffin D. Mechanisms of suppression of cell mediated immunity by measles virus. Science 1996;273:228-231.
169. Marie JC, Kehren J, Trescol-Biemont MC, Evlashev A, Valentin H, Walzer T, Tedone R, Loveland B, Nicolas JF, Rabourdin-Combe C, Horvat B. Mechanism of measles virus induced suppression of inflammatory responses. Immunity 2001;14:69-79.
170. American Academy of Pediatrics. Measles immunization in HIV-infected children. Committee on Infectious Disease and Committee on Pediatric AIDS. Pediatrics 1999;103:1057-1060.
171. Immunization Safety Review. Multiple immunization and immune dysfunction. Washington, DC: Institute of Medicine; 2002.
172. Siegrist C-A. Neonatal and early life vaccinology. Vaccine 2001;19:3331-3334.
173. Barrios C, Brawand P, Berney M, Brandt C, Lambert PH, Siegrist CA. Neonatal and early life immune responses to various forms of vaccine antigens qualitatively differ from adult responses: predominance of a Th2-biased pattern which persists in adult boosting. Eur J Immunol 1996;26:1489-1496.
174. Adkins B. Development of neonatal Th1/Th2 function. Int Rev Immunol 2000;19:157-171.
175. Adderson EE. Antibody repertories in infants and adults: effects of T-independent and T-dependent immunization. Springer Semin Immunopathol 2001;23:387-403.
176. Lee CJ, Lee LH, Frasch CE. Protective immunity of pneumococcal glycoconjugates. Crit Rev Microbiol 2003;29:333-349.
177. Anderson P, Smith DH, Ingram DL, Wilkins J, Wehrle PF, Howie VM. Antibody to polyribophate of Haemophilus influenzae type b in infants and children: effect of immunization with polyribophosphate. J Infect Dis 1977;136:S57-S62.
178. Muthukkuma RS, Goldstein J, Stein KE. The ability of B cells and dendritic cells to present antigen increases during ontogeny. J Immunol 2000;165:4803-4813.
179. Wedderburn LR, Patel A, Varsani H, Woo P. The developing human immune system: T cell receptor repertoire of children and young adults shows a wide discrepancy in the frequency of persistent oligoclonal T cell expansions. Immunology 2001;102:301-309.
180. Makela PH, Kayhty H, Leino T, Auranen K, Peltola H, Elkstrom N, Eskola J. Long-term persistence of immunity after immunization with Haemophilus influenzae type b conjugate vaccine. Vaccine 2003;22:287-292.
181. MMWR. Food and Drug Administration approval of use of a Haemophilus b conjugate vaccine for infants. Morb Mortal Wkly Rep 1990;39:925-926.
182. Lawrence D, Vaughn M, Belman A, Cole J, Rall G. Immune response modified protection of adult but not neonatal mice from neuron restricted measles virus infection and central nervous system disease. J Virol 1999;73:1975-1801.
183. Tishon A, Manchester M, Scheiflinger F, Oldstone MBA. A model of measles virus induced immunosuppression:enhanced susceptibility of neonatal human PBLs. Nat Med 1996;2:1250-1254.
184. Corbel MJ. Control testing of combined vaccines: a consideration of potential problems and approaches. Biologicals 1994;22:353-360.
185. Insel RA. Potential alterations in immunogenicity by combining or simultaneously administering vaccine components. Ann N Y Acad Sci 1995;754:35-47.
186. Dagan R, Eskola J, Leclerc C, Leroy O. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect Immun 1998;66:2093-2098.
187. Eskola J, Ward J, Dagan R, Goldblatt D, Zepp F, Siegrist CA. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus- pertussis containing acellular pertussis. Lancet 1999;354:2063-2068.
188. Gupta RK, Anderson R, Cecchini D, Rost B, Xu J, Gendreau K, Saroff DL, Marchant C, Siber GR. Evaluation of a guinea pig model to assess interference in the immunogenicity of different components of a combination vaccine comprising diphtheria, tetanus, and acellular pertussis (DTaP) vaccine and haemophilus influenzae type b capsular polysaccharide conjugate vaccine. Biologicals 1999;27:167-176.
189. Sesardic D, Dawes CS, McIellan K, Durrani Z, Yost SE, Corbel MJ. Non-pertussis components of combination vaccines: problems with potency testing. Biologicals 1999;27:177-181.
190. Granoff DM. Assessing efficacy of Haemophilus influenzae type b combination vaccines. Clin Infect Dis 2001;33:S278-S287.
191. Rennels MB, Englund JA, Bernstein DI, Losonsky GA, Anderson EL, Pichichero ME, Munoz FM, Wolff MC. Diminution of the anti-polyribosylribitol phosphate response to combined diphtheria-tetanus-acellular pertussis/ Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccine. Pediatr Infect Dis 2000;19:417-423.
192. Fattom A, Cho YH, Chu C, Fuller S, Fries L, Naso R. Epitopic overload at the site of injection may result in suppression of immune response to combined capsular polysaccharide conjugate vaccines. Vaccine 1999;17:126-133.
193. Gellin BG, Maibach EW, Marcuse EK. Do parents understand immunizations? A national telephone survey. Pediatrics 2000;106:1097-1102.
194. Offit PA, Quarles J, Gerber MA, Hackett CJ, Marcuse EK, Kollman TR, Gellin BG, Landry S. Addressing parents' concerns: do multiple vaccines overwhelm or weaken the infant's immune system? Pediatrics 2002;109:124-128.
195. Krober MS, Stracener CE, Bass JW. Decreased measles antibody response after measles-mumps-rubella vaccine in infants with colds. J Am Med Assoc 1991;265:2095-2096.
196. Kaslow RA, Evans A S. Epidemiologic concepts and methods. In: Evans AS, Kaslow RA, editors. Viral infections of humans: epidemiology and control. 4th ed. New York: Plenum Medical Book Co; 1997: p. 3-58.
197. Evans AS, Kaslow RA, editors. Viral infections of humans: epidemiology and control. 4th ed. New York: Plenum Medical Book Co; 1997.
198. Mims CA. The pathogenesis of infectious disease. 3rd ed. London: Academic Press; 1987.
199. Katayama Y, Kohso K, Nishimura A, Tatsuno Y, Homma M, Hotta H. Detection of measles virus mRNA from autopsied human tissues. J Clin Micro 1998;36:299-301.
200. Nakata Y, Nakayama T, Ide Y, Kizu R, Koinuma G, Bamba M. Measles virus genome detected up to four months in a case of congenital measles. Acta Paediatr 2002;91:1263-1265.
201. Schneider-Schaulies S, Schneider-Schaulies J, Dunster L, ter Meulen V. Measles virus gene expression in neural cells. Curr Top Microbiol Immunol 1995;191:101-116.
202. Marchalonis JJ. The immune response to infection. In: Ryan KJ, editors. Sherris medical microbiology. New York: McGraw-Hill; 2003: p. 115-140.
203. Permar SR, Klumpp SA, Mansfield KG, Kim WK, Gargone DA, Lifton MA Williams KC, Schmitz JE, Reimann KA, Axthelm MK, Polack FP, Griffin DE, Letwin NL. Role of CD8+ lymphocytes in control and clearance of measles virus infection of rhesus monkeys. J Virol 2003;77:4396-4400.
204. Chougnet C, Wynn TA Clerici M, Landay AL, Kessler HA, Rusnak J, Melcher GP, Sher A, Shearer GM. Molecular analysis of decreased interleukin-12 production in persons infected with human immunodeficiency virus. J Infect Dis 1996;174:46-53.
205. Watson RR, Dehghanpisheh K, Huang DS, Wood S, Ardestani SK, Laing B, et al. T-cell receptor V CDR1 peptide administration moderates immune dysfunction and cytokine dysregulation induced by murine retrovirus infection. J Immunol 1995;155:2282-2291.
206. Hoffman SK, Polack FP, Hauer DA, Singh M, Billeter MA, Adam RJ, Griffin DE. Vaccination of rhesus macaques with a recombinant measles virus expressing interleukin-12 alters humoral and cellular immune responses. J Infect Dis 2003;188:1553-1561.
207. Vuorinen T, Peri P, Vainionpaa R. Measles virus induces apoptosis in uninfected bystander T cells and leads to granzyme B and caspase activation in peripheral blood mononuclear cell cultures. Eur J Clin Invest 2003;33:434-442.
208. Schneider-Schaulies J, Klagge I, ter Meulen V. Dendritic cells and measles virus infection. Curr Top Microbiol Immunol 2003;276:77-101.
209. Murabayashi N, Kurita-Taniguchi M, Ayata M, Matsumoto M, Ogura H, Seya T. Susceptibility of human dendritic cells (DCs) to measles virus (MV) depends on their activation stages in conjunction with the level of CDw150: role of Toll stimulators in DC maturation and MV amplification. Microbes Infect 2002;4:785-794.
210. Manchester M, Smith KA, Eto DS, Perkin HB, Torbett BE. Targeting and hemotopoietic suppression of human CD34+ cells by measles virus. J Virol 2002;76:6636-6642.
211. Tamashiro VG, Perez HH, Griffin DE. Prospective study of the magnitude and duration of changes in tuberculin reactivity during uncomplicated and complicated measles. Pediatr Infect Dis J 1987;6:451-454.
212. Yanagi Y, Ono N, Tasuo H, Hashimoto K, Minagawa H. Measles virus receptor SLAM (CD150). Virology 2002;299:155-161.
213. Tatsuo H, Ono N, Tanaka K, Yanagi Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature 2000;406:893-897.
214. Fauci AS. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 1995;262:1011-1018.
215. Liszewski MK, Post TW, Atkinson JP. Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu Rev Immunol 1991;9:431-455.
216. Schneider-Schaulies S, ter Meulen V. Modulation of immune function by measles virus. Springer Semin Immunopathol 2002;24:127-148.
217. Auwaerter PG, Hussey GD, Goddard EA, Hughes J, Ryon JJ, Strebel PM, Beatty D, Griffin DE. Changes within T cell receptor Vβ subsets in infants following measles vaccination. Clin Immunol Pathol 1996;79:163-170.
218. Bieback K, Breer C, Nanan R, Volker ter Meulen V, Schneide-Schaulies S. Expansion of human γ/δ T cells in vitro is differentially regulated by the measles virus glycoproteins. J Gen Virol 2003;84:1170-1188.
219. Moss WJ, Ryon JJ, Monze M, Griffin DE. Differential regulation of interleukin (IL)-4, IL-5, and IL-10 during measles in Zambian children. J Infect Dis 2002;186:879-887.
220. Rager-Zisman B, Bazarsky E, Skibin A, Chamney S, Belmaker H, Shai I, Kordysh E, Griffin DE. The effect of measles-mumps-rubella (MMR) immunization on the immune response of previously immunized primary school children. Vaccine 2003;21:2580-2588.
221. Rall GF. Measles virus 1998-2002: progress and controversy. Annu Rev Microbiol 2003;57:343-367.
222. Slifka MK, Homann D, Tishon A, Pagarigan R, Oldstone MB. Measles virus infection results in suppression of both innate and adaptive immune responses to secondary bacterial infection. J Clin Invest 2003;111:805-810.
223. Pabst HF, Spady DW, Pilarshki LM, Carson MM, Beeler JA, Krezolek MP. Differential modulation of the immune response by breast-formula-feeding of infants. Acta Pediatr 1997;86:1291-1297.
224. Hussey GD, Goddard EA, Hughes J, Ryon JJ, Kerran M, Carelse E, Strebel PM, Markowitz LE, Moodie J, Barron P, Latief Z, Sayed R, Beatty D, Griffin DE. The effect of Edmonston-Zagreb and Schwartz measles vaccines on immune responses in infants. J Infect Dis 1996;173:1320-1326.
225. Parronchi P, Maggi E, Romagnani S. Redirecting Th2 responses in allergy. Curr Top Microbiol Immunol 1999;238:27-56.
226. Griffin DE, Ward BJ, Esolen MM. Pathogenesis of measles virus infection: an hypothesis for altered immune responses. J Infect Dis 1994;170:S24-31.
227. Leon ME, Ward BJ, Kanashiro R, Hernandex H, Berry S, Vaisberg A, Escamilla J, Campos M, Bellomo S, Azabache V. Immunologic parameters 2 years after high-titer measles immunization in Peruvian children. J Infect Dis 1993;168:1097-1104.
228. Aaby P, Knudsen K, Whittle H, Lisse ID, Thaarup J, Poulsen A, Sodemann M, Jakbosen M, Brink L, Gansted U, Permin A, Jenses TG, Andersen H, de Silva MC. Long-term survival after Edmonston-Zagreb measles vaccination in Guinea-Bissau: increased female mortality rate. J Pediatr 1993;122:904-908.
229. Aaby P, Jensen H, Simondon F, Whittle H. High-titre measles vaccination before 9 months of age and increased female mortality: do we have an explanation? Semin Pediatr Infect Dis 2003;14:220-232.
230. Imani F, Kehoe KE. Infection of human B lymphocytes with MMR vaccine induces IgE class switching. Clin Immunol 2001;100:355-361.
231. Okada H, Kobune F, Sato TA, Kohama T, Takeuchi Y, Abe T, Takayama N, Tshuchiya T, Tashiro M. Extensive lymphopenia due to apoptosis of uninfected lymphocytes in acute measles patients. Arch Virol 2000;145:805-920.
232. Hilleman MR. Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications. Vaccine 2001;20:651-665.
233. Arpadi SM, Markowitz LE, Baughman AL, Shah K, Adam H, Wiznia A, Lambert G, Dobroszycki J, Heath JL, Bellini WJ. Measles antibody in vaccinated human immunodeficiency virus type 1-infected children. Pediatrics 1996;97:653-657.
234. Atkins GJ, Cosby SL. Is an improved measles-mumps-rubella vaccine necessary or feasible? Crit Rev Immunol 2003;23:323-338.